1. Home
  2. Stocks
  3. Indoco Share Price

Indoco Remedies Share Price

Pharmaceuticals Small Cap

₹312.25 +3.8 (1.23%)

05 Nov, 2024 17:30

SIP TrendupStart SIP in INDOCO

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹307
  • High
  • ₹315
  • 52 Week Low
  • ₹287
  • 52 Week High
  • ₹415
  • Open Price₹307
  • Previous Close₹308
  • Volume36,619

Investment Returns

  • Over 1 Month -6.69%
  • Over 3 Month -4.14%
  • Over 6 Month -7.54%
  • Over 1 Year -2.44%
SIP Lightning

Smart Investing Starts Here Start SIP with Indoco Remedies for Steady Growth!

Indoco Remedies Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 89.8
  • PEG Ratio
  • -1.3
  • Market Cap Cr
  • 2,878
  • P/B Ratio
  • 2.6
  • Average True Range
  • 10.86
  • EPS
  • 11.7
  • Dividend Yield
  • 0.5
  • MACD Signal
  • -10.91
  • RSI
  • 33.67
  • MFI
  • 25.19

Indoco Remedies Financial

IndicatorSep 24Jun 24Mar 24Dec 23Sep 23
Net Sales/Income from operations396.53401.43445.49449.05473.39
Total Income From Operations396.53401.43445.49449.05473.39
P/L Before Interest, Excpt. Items & Tax32.1531.3937.6845.2552.13
P/L Before Exceptional Items & Tax17.3819.5126.7735.2244.03
P/L After Tax from Ordinary Activities12.7914.9537.5620.0133.14
Net Profit/Loss For the Period12.7914.9537.5620.0133.14
IndicatorMar 24Mar 23
Revenue From Operations [Gross]1,761.951,638.13
Revenue From Operations [Net]1,761.951,638.13
Total Operating Revenues1,790.811,666.69
Total Revenue1,799.321,669.02
Total Expenses1,657.621,477.43
Profit/Loss Before Tax153.23191.59
Profit/Loss For The Period116.64141.36
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity176.78175.59
Net Cash Used In Investing Activity-301.70-205.31
Net Cash Used in Finance Activity122.4022.81
Net Inc/Dec In Cash And Equivalent-2.52-6.91
Cash And Equivalent End Of Year7.479.99
IndicatorMar 24Mar 23
Total Share Capital18.4418.43
Total Non-Current Liabilities271.74205.41
Total Current Liabilities562.25427.24
Total Capital And Liabilities1,960.611,659.67
Total Non-Current Assets1,060.39852.62
Total Current Assets900.21807.05
Total Assets1,960.611,659.67
Indicator20242023
EBIT Margin (%)9.9612.99
Return On Capital Employed (%)12.7617.57
Return On Equity (%)10.3513.76
Long Term Debt To Equity (%)18.0713.97
Book Value/Share (INR)122.22111.45
IndicatorSep 24Jun 24Mar 24Dec 23Sep 23
Net Sales/Income from operations432.66431.49449.64459.42481.73
Total Income From Operations432.66431.49449.64459.42481.73
P/L Before Interest, Excpt. Items & Tax12.9921.2825.3040.9054.39
P/L Before Exceptional Items & Tax-4.846.9713.2530.8346.28
P/L After Tax from Ordinary Activities-10.011.8222.0315.5635.24
Net Profit/Loss For the Period-10.011.8222.0315.5635.24
IndicatorMar 24Mar 23
Revenue From Operations [Gross]1,788.221,640.05
Revenue From Operations [Net]1,788.221,640.05
Total Operating Revenues1,817.291,668.61
Total Revenue1,827.131,670.95
Total Expenses1,702.861,478.15
Profit/Loss Before Tax135.80192.79
Profit/Loss For The Period97.00142.25
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity156.70178.84
Net Cash Used In Investing Activity-433.83-208.17
Net Cash Used in Finance Activity280.4322.80
Net Inc/Dec In Cash And Equivalent3.93-6.53
Cash And Equivalent End Of Year14.8610.93
IndicatorMar 24Mar 23
Total Share Capital18.4418.43
Total Non-Current Liabilities421.90205.44
Total Current Liabilities612.33424.51
Total Capital And Liabilities2,144.731,658.20
Total Non-Current Assets1,190.06850.02
Total Current Assets954.67808.18
Total Assets2,144.731,658.20
Indicator20242023
EBIT Margin (%)8.9313.05
Return On Capital Employed (%)10.5917.65
Return On Equity (%)8.8713.83
Long Term Debt To Equity (%)31.6813.95
Book Value/Share (INR)120.47111.58

Indoco Remedies Technicals

EMA & SMA

Current Price
₹312.25
+ 3.8 (1.23%)
pointer
  • stock-down_img
  • Bullish Moving Average 3
  • stock-up_img
  • Bearish Moving Average 13
  • 20 Day
  • ₹323.06
  • 50 Day
  • ₹335.93
  • 100 Day
  • ₹339.14
  • 200 Day
  • ₹341.04

Resistance and Support

310.32 Pivot Speed
  • R3 319.73
  • R2 317.22
  • R1 312.83
  • S1 305.93
  • S2 303.42
  • S3 299.03

Is Indoco Remedies Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Indoco Remedies Ltd. is a leading Indian pharmaceutical company specializing in the manufacturing and marketing of generic formulations, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. The company focuses on quality, innovation, and compliance across various therapeutic segments. Indoco Remedies has an operating revenue of Rs. 1,773.21 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 7% is okay, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 32%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 45 which is a POOR score indicating inconsistency in earnings, a RS Rating of 23 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Indoco Remedies Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-24 Quarterly Results
2024-07-23 Quarterly Results
2024-05-16 Audited Results & Final Dividend
2024-01-23 Quarterly Results
2023-10-19 Quarterly Results

Indoco Remedies F&O

Indoco Remedies Shareholding Pattern

58.75%
16.74%
0.13%
1.7%
16.3%
6.38%
  • NSE Symbol
  • INDOCO
  • BSE Symbol
  • 532612
  • Managing Director
  • Ms. Aditi Panandikar
  • ISIN
  • INE873D01024

Indoco Remedies FAQs

Indoco Remedies share price is ₹312 As on 05 November, 2024 | 17:16

The Market Cap of Indoco Remedies is ₹2878.4 Cr As on 05 November, 2024 | 17:16

The P/E ratio of Indoco Remedies is 89.8 As on 05 November, 2024 | 17:16

The PB ratio of Indoco Remedies is 2.6 As on 05 November, 2024 | 17:16

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.